Lisinopril activates BI1 to reprogram lipid metabolism and restore autophagy in ALS

Read full text Summarise with VIRAT
Authors: Hanlan Yin, Zhichao Ren, Yan Zhang, Yuxiang Wang, Yiyang Sun, Xueqi Fu, Wenfu Yan, Fuqiang Zhang, LINLIN ZENG
Cited by: 0
References: 58

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Amyotrophic lateral sclerosis (ALS) involves disrupted lipid metabolism. Bax inhibitor 1 (BI1), an endoplasmic reticulum protein downregulated in ALS neuroprotective, represents a therapeutic target, but its metabolic regulatory mechanisms are incompletely understood. Using transcriptomics in skeletal muscle of ALS mice pre- and post-BI1 treatment, we identified BI1-regulated pathways. Structure-based virtual screening of FDA-approved compounds nominated lisinopril as a BI1 activator. Lisinopril upregulated BI1 protein expression, stabilizing mitochondrial membrane potential and protecting against SOD1G93A-induced apoptosis in NSC34 cells. Concurrently, it regulated TGF-β1/mTOR-dependent autophagy, maintained NMJ integrity, and reshaped triglyceride/sphingolipid/glycerophospholipid metabolism to attenuate spinal cord pathology in ALS mice, promoting energy metabolism shift toward glucose oxidation. Additionally, lisinopril inhibited the TGF-β1/Smad2/3 pathway to alleviate muscle fibrosis, downregulate Acp5/FN expression, and reduce type I collagen deposition. In conclusion, this study provides evidence that pharmacological activation of BI1 by lisinopril suppresses TGF-β1, modulates lipid metabolism, and ameliorates ALS pathology, demonstrating promising therapeutic repurposing potential. Lisinopril is identified as a BI1 activator that counteracts ALS pathology. It remodels lipid metabolism, restores autophagic flux via TGFβ1/mTOR signaling, and mitigates fibrosis. This multi-target mechanism supports the therapeutic repurposing of lisinopril for ALS.

Fields of Study & Subjects

Amyotrophic Lateral Sclerosis Research Alzheimer's disease research and treatments Muscle Physiology and Disorders

Publication details

Journal / source
Communications Biology
Volume
9
Issue
1
Pages
705
Publication date
31 March 2026
Language
EN